^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Published date:
12/02/2023
Excerpt:
This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma....Median overall survival was 21·2 months (95% CI 19·0-23·6; 252 [64%] of 395 died) with lenvatinib plus pembrolizumab versus 19·0 months (17·2-21·7; 282 [71%] of 399 died) with lenvatinib plus placebo (hazard ratio [HR] 0·84; 95% CI 0·71-1·00; stratified log-rank p=0·023).
DOI:
10.1016/S1470-2045(23)00469-2
Trial ID:
